EXOZ
eXoZymes, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
7.15
▲ 0.11 (1.56%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
6.68
Prev close
7.04
Day high
7.98
Day low
7.08
Volume
10.10K
Market cap
$66.36M
P/E (TTM)
—
52W range
4.35 – 18.40
Day trading desk
Gap from prior close
-5.11%
Prior close 7.04
VWAP
7.36
-2.84% from price
Relative volume
1.09×
Normal
Session range
27.14%
6.67 – 8.48
Position in range
27%
Near session low
ATR (14D)
0.57
8.03% of price
Prior day high
7.71
PDH
Prior day low
6.42
PDL
Bid / ask spread
—
Quote not published
Session volume
10.42K
Avg 9.57K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+22.85%
+24.2%
1M
+52.13%
+48.4%
3M
-23.94%
-27.0%
6M
-19.66%
-30.7%
YTD
-34.40%
-46.7%
1Y
-26.93%
-46.9%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on EXOZ open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+85.48K
Net buying
Buy transactions
5
86.98K shares
Sell transactions
1
1.50K shares
Net transactions
+6
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
5.99M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 9, 26 | KORMAN TYLER PAZ PH.D. Officer |
SELL | 1.50K | $15.42K | Direct |
| Apr 1, 26 | OPGENORTH PAUL HIDEO Officer |
STOCK | 4.00K | $33.75K | Direct |
| Apr 1, 26 | NAWAZ FOUAD Officer |
STOCK | 6.00K | $50.63K | Direct |
| Apr 1, 26 | KORMAN TYLER PAZ PH.D. Officer |
STOCK | 5.33K | $45.00K | Direct |
| Apr 1, 26 | PERRIMAN DAMIEN ALAN MBA Officer |
STOCK | 8.89K | $75.01K | Direct |
| Apr 1, 26 | PERRIMAN DAMIEN ALAN MBA Officer |
STOCK | 62.76K | $0 | Direct |
| Jul 2, 25 | HELTZEN MICHAEL Chief Executive Officer |
BUY | 1.04K | $10.63K | Direct |
| Jun 16, 25 | KORMAN TYLER PAZ PH.D. Officer |
STOCK | 2.99K | $37.49K | Direct |
| Jun 13, 25 | OPGENORTH PAUL HIDEO Officer |
STOCK | 2.99K | $37.49K | Direct |
| Jun 13, 25 | NAWAZ FOUAD Officer |
STOCK | 3.49K | $43.75K | Direct |
| Jan 17, 25 | HELTZEN MICHAEL Chief Executive Officer |
BUY | 1.89K | $20.34K | Direct |
| Nov 15, 24 | HELTZEN MICHAEL Chief Executive Officer |
BUY | 1.98K | $22.02K | Direct |
| Nov 8, 24 | MDB CAPITAL HOLDINGS, LLC Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 122.66K | $785.00K | Direct |
| Nov 8, 24 | OPGENORTH PAUL HIDEO Officer |
CONVERSION | 2.34K | $15.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HELTZEN MICHAEL |
Chief Executive Officer | 10.63K | Purchase |
KORMAN TYLER PAZ PH.D. |
Officer | 729.12K | Sale |
MDB CAPITAL HOLDINGS, LLC |
Beneficial Owner of more than 10% of a Class of Security | 3.93M | Conversion of Exercise of derivative security |
NAWAZ FOUAD |
Officer | 9.49K | Stock Award(Grant) |
OPGENORTH PAUL HIDEO |
Officer | 645.15K | Stock Award(Grant) |
PERRIMAN DAMIEN ALAN MBA |
Officer | 8.89K | Stock Award(Grant) |
Fundamentals
Market cap$66.36M
Enterprise value$61.79M
Revenue (TTM)—
Gross profit—
EBITDA$-10.26M
Net income$-10.19M
EPS (TTM)$-1.20
Free cash flow$-3.25M
Total cash$5.65M
Total debt$1.09M
Book value / share$0.39
Shares outstanding9.28M
Float7.20M
Short % of float0.44%
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book18.15
EV / revenue—
EV / EBITDA-6.02
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-187.16%
Return on assets-74.74%
Debt / equity29.69
Current ratio3.81
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $3.71M | $1.87M | $527.48K | $376.68K | +98.4% |
| Selling, general & admin | $6.01M | $4.06M | $1.34M | $984.58K | +47.9% |
| Total operating expense | $9.72M | $5.93M | $1.80M | $1.33M | +63.8% |
| Operating income | -$9.72M | -$5.93M | -$1.80M | -$1.33M | -63.8% |
| Net interest income | $363.79K | $77.61K | $100 | $98 | +368.7% |
| Pre-tax income | -$9.26M | -$5.86M | -$2.00M | -$1.33M | -58.1% |
| Tax provision | -$105.20K | $0 | $42.27K | $63.56K | — |
| Net income | -$9.16M | -$5.86M | -$2.04M | -$1.40M | -56.3% |
| Net income to common | -$9.16M | -$5.86M | -$2.04M | -$1.40M | -56.3% |
| Basic EPS | -1.09 | -0.89 | -0.25 | -0.17 | -22.5% |
| Diluted EPS | -1.09 | -0.89 | -0.25 | -0.17 | -22.5% |
| EBIT | -$9.72M | -$5.93M | -$1.80M | -$1.33M | -63.8% |
| EBITDA | -$9.43M | -$5.66M | -$1.60M | -$1.18M | -66.4% |
| Basic shares | 8.38M | 6.56M | 8.13M | 8.13M | +27.7% |
| Diluted shares | 8.38M | 6.56M | 8.13M | 8.13M | +27.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.04M | $9.72M | $66.53K | $558.57K | -68.7% |
| Cash & short-term investments | $3.04M | $9.72M | $66.53K | $558.57K | -68.7% |
| Total current assets | $3.94M | $10.82M | $1.21M | $1.47M | -63.6% |
| Property, plant & equipment | $1.93M | $2.21M | $2.34M | $1.22M | -13.0% |
| Total assets | $5.97M | $13.03M | $3.56M | $2.69M | -54.2% |
| Total current liabilities | $1.57M | $1.33M | $2.42M | $634.36K | +17.5% |
| Total debt | $1.24M | $1.39M | $1.61M | $608.77K | -10.4% |
| Total liabilities | $2.57M | $2.61M | $3.94M | $1.31M | -1.5% |
| Retained earnings | -$21.10M | -$11.95M | -$6.08M | -$4.05M | -76.7% |
| Shareholder equity | $3.40M | $10.42M | -$384.32K | $1.37M | -67.4% |
| Working capital | $2.37M | $9.49M | -$1.20M | $834.88K | -75.0% |
| Net tangible assets | $3.40M | $10.42M | -$384.32K | $1.37M | -67.4% |
| Shares issued | 8.41M | 8.37M | 8.13M | 8.13M | +0.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$9.16M | -$5.86M | -$2.04M | -$1.40M | -56.3% |
| Depreciation & amortisation | $287.96K | $267.38K | $196.94K | $147.75K | +7.7% |
| Stock-based compensation | $1.99M | $1.13M | $281.54K | $216.50K | +76.6% |
| Change in working capital | $380.17K | -$4.02M | $220.31K | -$190.07K | +109.5% |
| Operating cash flow | -$6.50M | -$8.51M | -$1.18M | -$1.26M | +23.6% |
| Capital expenditure | -$169.92K | -$396.45K | -$288.71K | -$185.98K | +57.1% |
| Investing cash flow | -$150.22K | -$359.22K | -$311.17K | -$87.21K | +58.2% |
| Financing cash flow | -$27.71K | $18.52M | $1.00M | $1.36M | -100.1% |
| Free cash flow | -$6.67M | -$8.90M | -$1.47M | -$1.44M | +25.1% |
| End cash position | $3.04M | $9.72M | $66.53K | $558.57K | -68.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $1.12M | $1.11M | $1.22M | $802.99K | $575.02K | +0.8% |
| Selling, general & admin | $1.27M | $1.58M | $1.31M | $1.75M | $1.38M | -20.0% |
| Total operating expense | $2.39M | $2.70M | $2.52M | $2.55M | $1.95M | -11.4% |
| Operating income | -$2.39M | -$2.70M | -$2.52M | -$2.55M | -$1.95M | +11.4% |
| Net interest income | $13.72K | $132.04K | $59.19K | $76.56K | $94.31K | -89.6% |
| Pre-tax income | -$2.37M | -$2.76M | -$2.29M | -$2.36M | -$1.86M | +14.1% |
| Tax provision | $0 | -$105.20K | $0 | $0 | $0 | +100.0% |
| Net income | -$2.37M | -$2.66M | -$2.29M | -$2.36M | -$1.86M | +10.7% |
| Net income to common | -$2.37M | -$2.66M | -$2.29M | -$2.36M | -$1.86M | +10.7% |
| Basic EPS | -0.28 | — | -0.27 | -0.28 | -0.22 | — |
| Diluted EPS | -0.28 | — | -0.27 | -0.28 | -0.22 | — |
| EBIT | -$2.39M | -$2.70M | -$2.52M | -$2.55M | -$1.95M | +11.4% |
| EBITDA | -$2.31M | -$2.62M | -$2.45M | -$2.48M | -$1.88M | +11.8% |
| Basic shares | 8.46M | — | 8.39M | 8.38M | 8.37M | — |
| Diluted shares | 8.46M | — | 8.39M | 8.38M | 8.37M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.44M | $3.04M | $5.10M | $6.99M | $8.51M | -52.5% |
| Cash & short-term investments | $1.44M | $3.04M | $5.10M | $6.99M | $8.51M | -52.5% |
| Total current assets | $2.09M | $3.94M | $5.61M | $7.53M | $9.42M | -46.9% |
| Property, plant & equipment | $1.82M | $1.93M | $2.01M | $2.15M | $2.11M | -5.3% |
| Total assets | $4.02M | $5.97M | $7.72M | $9.68M | $11.53M | -32.7% |
| Total current liabilities | $1.58M | $1.57M | $1.24M | $1.22M | $1.44M | +1.0% |
| Total debt | $1.16M | $1.24M | $1.32M | $1.39M | $1.33M | -6.3% |
| Total liabilities | $2.49M | $2.57M | $2.34M | $2.44M | $2.64M | -3.2% |
| Retained earnings | -$23.47M | -$21.10M | -$18.45M | -$16.16M | -$13.80M | -11.2% |
| Shareholder equity | $1.53M | $3.40M | $5.37M | $7.24M | $8.88M | -55.0% |
| Working capital | $507.58K | $2.37M | $4.37M | $6.31M | $7.97M | -78.6% |
| Net tangible assets | $1.53M | $3.40M | $5.37M | $7.24M | $8.88M | -55.0% |
| Shares issued | 8.48M | 8.41M | 8.39M | 8.39M | 8.37M | +0.9% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.37M | -$2.66M | -$2.29M | -$2.36M | -$1.86M | +10.7% |
| Depreciation & amortisation | $74.15K | $73.60K | $71.60K | $72.26K | $70.50K | +0.7% |
| Stock-based compensation | $501.10K | $677.87K | $425.71K | $567.25K | $317.28K | -26.1% |
| Change in working capital | $261.66K | -$73.03K | -$77.21K | $189.16K | $341.25K | +458.3% |
| Operating cash flow | -$1.52M | -$1.97M | -$1.86M | -$1.54M | -$1.13M | +22.8% |
| Capital expenditure | -$57.60K | -$74.99K | -$13.31K | -$50.57K | -$31.05K | +23.2% |
| Investing cash flow | -$57.60K | -$74.99K | -$13.31K | -$30.87K | -$31.05K | +23.2% |
| Financing cash flow | -$12.74K | -$10.55K | -$17.16K | $43.25K | -$43.25K | -20.7% |
| Free cash flow | -$1.58M | -$2.05M | -$1.87M | -$1.59M | -$1.16M | +22.8% |
| End cash position | $1.44M | $3.04M | $5.10M | $6.99M | $8.51M | -52.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders64.53%
Held by institutions1.34%
Institutions holding10
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.16
+16.17% from price
SMA 20
5.45
+31.10% from price
SMA 50
6.39
+11.85% from price
SMA 100
8.14
-12.11% from price
SMA 200
9.69
-26.21% from price
EMA 12
6.16
+16.11% from price
EMA 26
6.01
+19.03% from price
EMA 50
6.51
+9.91% from price
RSI (14)
67.3
Neutral
MACD (12,26,9)
0.15
Hist 0.31
ATR (14)
0.57
8.03% of price
Realised vol 30D
98.1%
Annualised
Bollinger upper
7.14
20, 2σ
Bollinger lower
3.77
20, 2σ
50 / 200 cross
Death
6.39 vs 9.69
Trend bias
Below 200
-26.21%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.12
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
98.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-73.3%
Peak to trough
Max drawdown 5Y
-78.6%
Peak to trough
ATR 14
0.57
8.03% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
21.89K
Prior 15.72K
Change vs prior
+39.3%
Shorts adding
% of float
0.44%
Normal
% of shares out
0.24%
Against total outstanding
Days to cover
1.6
Liquid
Float
7.20M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
SEC filings
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-01
Corporate Changes & Voting Matters
8-K · 2026-06-26
Corporate Changes & Voting Matters
8-K · 2026-06-17
Periodic Financial Reports
10-Q · 2026-05-14
Corporate Changes & Voting Matters
8-K · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-04-10
Corporate Changes & Voting Matters
8-K · 2026-03-31
Headlines
EXoZymes Inc (EXOZ) (Q2 2026) Earnings Call Highlights: Strategic Pivot and 10x Productivity ...
GuruFocus.com · 2d ago
eXoZymes Q2 Earnings Call Highlights
MarketBeat · 3d ago
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
ACCESS Newswire · 3d ago
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
ACCESS Newswire · 5d ago
MDB Capital Holdings LLC (MDBH) (Q2 2026) Earnings Call Highlights: Strategic Pivots and Asset ...
GuruFocus.com · 6d ago
MDB Capital Holdings Provides Second Quarter 2026 Update
GlobeNewswire · 10d ago
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
ACCESS Newswire · 12d ago
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
ACCESS Newswire · 31d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.